BATF2 Reverses Multidrug Resistance of Human Gastric Cancer Cells by Suppressing Wnt/β-catenin Signaling

Overview

Journal In Vitro Cell Dev Biol Anim

Publisher Springer

Specialties Biology
Cell Biology

Date 2019 May 30

PMID 31140101

Citations 9

Authors

Wei Yang

Bian Wu

Ning Ma

Yongfang Wang

Jianhui Guo

Jun Zhu

Sihui Zhao

Affiliations

Soon will be listed here.

Abstract

Gastric cancer (GC) is a commonly occurring neoplasm worldwide. The occurrence of multidrug resistance (MDR) in GC cells is the main obstacle to effective GC chemotherapy. The aim of the present study was to reveal the functional role and the underlying mechanisms of basic leucine zipper ATF-like transcription factor 2 (BATF2), a novel tumor suppressor, on MDR in GC cells. Here, we first found that SGC7901/VCR and SGC7901/ADR cells had higher drug resistance than SGC7901 cells using methylthiazol tetrazolium (MTT) and flow cytometry analysis. Moreover, MDR-related proteins and Wnt/β-catenin pathway markers were all upregulated in SGC7901/VCR cells compared to SGC7901 cells by quantitative reverse transcription-PCR (qRT-PCR) and western blot analyses. Subsequently, we observed BATF2 was downregulated in SGC7901/VCR cells and BATF2 overexpression significantly induced cell cycle G0/G1 phase arrest and apoptosis. Furthermore, overexpression of BATF2 could suppress Wnt/β-catenin signaling and increase drug susceptibility by downregulating Wnt/β-catenin pathway markers. In addition, knockdown of β-catenin imitated the effects of BATF2 overexpression on drug susceptibility. Importantly, enhancing the Wnt/β-catenin pathway could reverse the inhibitory effects of BATF2 on MDR. In conclusion, BATF2 was downregulated in MDR GC cells and overexpression of BATF2 could reverse the MDR of GC cells by inactivating the Wnt/β-catenin pathway.

Citing Articles

Wnt signaling in gastric cancer: current progress and future prospects.

Han R, Yang J, Zhu Y, Gan R Front Oncol. 2024; 14:1410513.

PMID: 38952556 PMC: 11216096. DOI: 10.3389/fonc.2024.1410513.

Wnt signaling and tumors (Review).

Wang H, Zhang L, Hu C, Li H, Jiang M Mol Clin Oncol. 2024; 21(1):45.

PMID: 38798312 PMC: 11117032. DOI: 10.3892/mco.2024.2743.

Anti-ENO1 antibody combined with metformin against tumor resistance: a novel antibody-based platform.

Shu X, Zhang H, Liu S, Sun L, Zhang T, Ran Y PeerJ. 2024; 12:e16817.

PMID: 38515460 PMC: 10956521. DOI: 10.7717/peerj.16817.

Characterization of m6A methylation modifications in gastric cancer.

Yin W, Huo Z, Zuo J, Wang H, Chen B, Zhou L Aging (Albany NY). 2024; 16(1):89-105.

PMID: 38206646 PMC: 10817395. DOI: 10.18632/aging.205341.

CD36-BATF2\MYB Axis Predicts Anti-PD-1 Immunotherapy Response in Gastric Cancer.

Jiang Q, Chen Z, Meng F, Zhang H, Chen H, Xue J Int J Biol Sci. 2023; 19(14):4476-4492.

PMID: 37781029 PMC: 10535701. DOI: 10.7150/ijbs.87635.

References

Tetsu O, McCormick F . Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999; 398(6726):422-6. DOI: 10.1038/18884. View

Yeh K, Shun C, Chen C, Lin J, Lee W, Lee P . Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy. Hepatogastroenterology. 1999; 46(25):610-5. View

Borst P, Evers R, Kool M, Wijnholds J . A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000; 92(16):1295-302. DOI: 10.1093/jnci/92.16.1295. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Gillet J, Efferth T, Remacle J . Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta. 2007; 1775(2):237-62. DOI: 10.1016/j.bbcan.2007.05.002. View

Klaus A, Birchmeier W . Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008; 8(5):387-98. DOI: 10.1038/nrc2389. View

Lim J, Kania K, Wijesuriya H, Chawla S, Sethi J, Pulaski L . Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008; 106(4):1855-65. PMC: 4303914. DOI: 10.1111/j.1471-4159.2008.05537.x. View

Su Z, Lee S, Emdad L, Lebdeva I, Gupta P, Valerie K . Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN). Proc Natl Acad Sci U S A. 2008; 105(52):20906-11. PMC: 2634918. DOI: 10.1073/pnas.0807975106. View

MacDonald B, Tamai K, He X . Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17(1):9-26. PMC: 2861485. DOI: 10.1016/j.devcel.2009.06.016. View

10.

Dash R, Su Z, Lee S, Azab B, Boukerche H, Sarkar D . Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1. Oncogene. 2010; 29(31):4412-23. DOI: 10.1038/onc.2010.194. View

11.

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

12.

Fodale V, Pierobon M, Liotta L, Petricoin E . Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance?. Cancer J. 2011; 17(2):89-95. PMC: 5558433. DOI: 10.1097/PPO.0b013e318212dd3d. View

13.

Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A . The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol. 2011; 22 Suppl 5:v1-9. DOI: 10.1093/annonc/mdr284. View

14.

Sun Y, Patel A, Kumar P, Chen Z . Role of ABC transporters in cancer chemotherapy. Chin J Cancer. 2012; 31(2):51-7. PMC: 3777472. DOI: 10.5732/cjc.011.10466. View

15.

Zhang H, Zhang X, Wu X, Li W, Su P, Cheng H . Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/β-catenin pathway. Cancer Lett. 2012; 323(1):106-113. DOI: 10.1016/j.canlet.2012.03.039. View

16.

Valenta T, Hausmann G, Basler K . The many faces and functions of β-catenin. EMBO J. 2012; 31(12):2714-36. PMC: 3380220. DOI: 10.1038/emboj.2012.150. View

17.

Bray F, Ren J, Masuyer E, Ferlay J . Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2012; 132(5):1133-45. DOI: 10.1002/ijc.27711. View

18.

Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian Z, Du J . Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012; 487(7408):500-4. PMC: 3711467. DOI: 10.1038/nature11183. View

19.

Lutz M, Zalcberg J, Ducreux M, Ajani J, Allum W, Aust D . Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 2012; 48(16):2941-53. DOI: 10.1016/j.ejca.2012.07.029. View

20.

Tussiwand R, Lee W, Murphy T, Mashayekhi M, Kc W, Albring J . Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature. 2012; 490(7421):502-7. PMC: 3482832. DOI: 10.1038/nature11531. View